肌缩侧面硬化症,内类药物系统和外源性大麻素:当前状态和临床影响
Travis T Denton1,2,3, Gregory T Carter2,3,4, Megan Goddard1
1Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University Health Sciences Spokane, Spokane, Washington, USA.
Muscle & nerve
|February 12, 2025
概括
大麻素在治疗肌缩性侧面硬化症 (ALS) 方面表现有前途. 临床前研究表明大麻提取物提供神经保护,而人类试验表明对ALS患者的运动和非运动症状有好处.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
背景情况:
- 肌缩侧面硬化症 (ALS) 缺乏明确的统一原因,具有多个同时发生的病理生理过程.
- 内激素系统 (ECS) 与ALS和其他神经退行性疾病有关,促使人们对大麻素产生兴趣.
研究的目的:
- 探索大麻素的治疗潜力,包括delta-9-tetrahydrocannabinol (THC),cannabidiol (CBD) 等,用于ALS治疗.
- 审查临床前和早期人类证据,以证明大麻素在ALS中的有效性.
主要方法:
- 在ALS的SOD1G93A小鼠模型中对临床前数据的审查.
- 对研究大麻和CBD用于ALS症状管理的有限人体研究的分析.
主要成果:
- 大麻提取物 (CEs) 在临床前ALS模型中显示出强大的抗氧化,抗炎和神经保护作用.
- 在小鼠模型中,CE延长了神经元细胞的存活时间,延迟了疾病的发病,并减缓了疾病的进展.
- 人类研究表明,大麻和CBD可以改善运动症状 (刚性,) 和非运动症状 (睡眠,疼痛,情绪,生活质量).
结论:
- 大麻素显示出作为ALS治疗策略的潜力,得到了临床前证据的支持.
- 需要进一步进行精心设计的临床试验,以验证大麻素作为ALS的疾病修饰疗法.
更多相关视频
12:35Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS
Published on: March 17, 2012
28.0K
10:49Intraspinal Cell Transplantation for Targeting Cervical Ventral Horn in Amyotrophic Lateral Sclerosis and Traumatic Spinal Cord Injury
Published on: September 18, 2011
20.6K
相关概念视频
01:24CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
156
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
156
01:25Analgesia and Pain Management
429
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
429
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
200
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
200
01:22Opioid Receptors: Overview
439
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
439
01:15Parkinson's Disease: Overview
436
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
436
01:15Drug Abuse and Addiction: Pharmacological Phenomena
430
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
430